Pipeline Watch: Phase III Readouts In Breast And Liver Cancer Plus COVID-19
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Finance Watch: 2021 Is Now Two Away From 100 Biopharma IPOs
Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.
Executives On The Move: Changes At SpineThera, Morphic Holding and More
Recent executive changes in the industry include C-suite changes at Zentalis Pharmaceuticals and Morphic Holding. Meanwhile, new directors were appointed at SpineThera and Avenue Therapeutics, among others.
Executives On The Move: Changes At Alligator Bioscience, Legend Biotech and More
Recent executive changes in the industry include C-suite changes at Legend Biotech and Seagen. Meanwhile, new directors were appointed at Alligator Bioscience and Kintor Pharmaceutical, among others.